<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04207723</url>
  </required_header>
  <id_info>
    <org_study_id>005</org_study_id>
    <nct_id>NCT04207723</nct_id>
  </id_info>
  <brief_title>Transcutaneous Posterior Tibial Nerve Stimulation for Premature Ejaculation</brief_title>
  <official_title>Effectiveness and Safety of Transcutaneous Posterior Tibial Nerve Stimulation for Premature Ejaculation Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Medical Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Medical Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: Evaluate the effectiveness and safety of transcutaneous electrostimulation of the&#xD;
      posterior tibial nerve alone and combined with standard pharmacological treatment, in men&#xD;
      with primary premature ejaculation, compared to standard pharmacological treatment.&#xD;
&#xD;
      Patients and methods: Randomized controlled clinical trial. Patients diagnosed with premature&#xD;
      ejaculation attending Boston Medical Group clinics in Colombia and Spain will be included.&#xD;
      Participants will be assigned by randomization to one of three treatment groups:&#xD;
&#xD;
        -  Group 1: Tens + placebo drug therapy&#xD;
&#xD;
        -  Group 2: Standard treatment (paroxetine 20 mg) + placebo therapy&#xD;
&#xD;
        -  Group 3: Tens therapy + standard treatment (paroxetine mg)&#xD;
&#xD;
      The change in intravaginal latency time measured with the couple's sustained stopwatch, the&#xD;
      change in the PEDT scale, the perception of the change in their initial condition after&#xD;
      treatment (Global Clinical impression of change scale), and the change in different domains&#xD;
      of the EP (PEP Scale - Profile Ejaculation Premature) at the end of treatment (week 12) and&#xD;
      at three months of follow-up (week 24).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intravaginal latency time at week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Mean change in intravaginal latency time, measured with a stopwatch by the couple, at week 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Premature Ejaculation Diagnostic Tool (PEDT) questionnaire score</measure>
    <time_frame>weeks 12 and 24</time_frame>
    <description>Patients with a change in Premature Ejaculation Diagnostic Tool questionnaire score at weeks 12 and 24. A score of 11 or more suggests PE. A score of 9 or 10 may be found in men with PE; it is a &quot;borderline&quot; score. A score of 8 or less suggests that a man does not have PE. The minimum and maximum values are 0 and 20, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement</measure>
    <time_frame>weeks 12 and 24</time_frame>
    <description>Three-fold increase in intravaginal ejaculatory latency time</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Premature Ejaculation</condition>
  <arm_group>
    <arm_group_label>TENS Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tens therapy + placebo drug therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Standard treatment (paroxetine 20 mg) + sham therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tens therapy + standard treatment (paroxetine 20 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Transcutaneous posterior tibial nerve stimulation</intervention_name>
    <description>Three (3) sessions per week per twelve (12) consecutive weeks, with a duration of 30 minutes each, with the application of 20 Hertz with a pulse amplitude of 200 MI sec. in each session. The intensity will be applied individually for each patient depending on the tolerance of the individual.</description>
    <arm_group_label>Combination therapy</arm_group_label>
    <arm_group_label>TENS Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paroxetine</intervention_name>
    <description>paroxetine 20 mg / day taken in the morning hours, per 12 weeks.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary premature ejaculation as defined by the International Society for Sexual&#xD;
             Medicine (ISSM-International Society for Sexual Medicine) (30): a) ejaculation occurs&#xD;
             always or almost always within the first minute after penetration, b) disability to&#xD;
             delay ejaculation in all or almost all penetrations, c) negative personal consequences&#xD;
             are generated, such as stress, discomfort, frustration and / or avoidance of sexual&#xD;
             intimacy.&#xD;
&#xD;
          -  Age equal to or greater than 18 years.&#xD;
&#xD;
          -  PEDT score greater than 11.&#xD;
&#xD;
          -  Stable heterosexual relationship of at least 6 months with the interest of maintaining&#xD;
             it for at least the duration of the study.&#xD;
&#xD;
          -  Sexual activity at least once a week.&#xD;
&#xD;
          -  Minimum chronicity of PE of 6 months.&#xD;
&#xD;
          -  Voluntary participation in the study.&#xD;
&#xD;
          -  Signature of informed consent prior to participation in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  IIEF-EF score greater than 25.&#xD;
&#xD;
          -  Clinically significant comorbidity: cardiovascular, hepatic, thromboembolic,&#xD;
             neurological, locomotive, endocrine, oncological, renal or rheumatologic.&#xD;
&#xD;
          -  History of retroperitoneal surgery, radiotherapy or multiple sclerosis.&#xD;
&#xD;
          -  History of mental illness: depression, anxiety, suicidal behavior, bipolar disorder,&#xD;
             agoraphobia, dysthymia, social phobia, obsessive compulsive disorder, post-traumatic&#xD;
             stress, psychiatric disorder, referred by the patient or by the use of a medication&#xD;
             for one of these terms.&#xD;
&#xD;
          -  Consumption of medications that affect ejaculatory control such as psychiatric&#xD;
             medications, opioid analgesics, alpha blockers.&#xD;
&#xD;
          -  Treatment for PD in the last 3 months.&#xD;
&#xD;
          -  Treatment for epileptic syndromes or Parkinson's disease.&#xD;
&#xD;
          -  Use of pacemaker or cardiac defibrillator.&#xD;
&#xD;
          -  Skin lesions in the electrode placement area.&#xD;
&#xD;
          -  Abuse or dependence on piscoactive substances: alcohol, hallucinogenic drugs.&#xD;
&#xD;
          -  Couple in a state of pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 19, 2019</study_first_submitted>
  <study_first_submitted_qc>December 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2019</study_first_posted>
  <last_update_submitted>December 27, 2019</last_update_submitted>
  <last_update_submitted_qc>December 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Premature Ejaculation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paroxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

